SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing high volatility as investors weigh the potential for a restrictive stablecoin bill against strong institutional interest and growth in the broader stablecoin market. The community remains deeply divided, with bulls pointing to robust transaction volumes and strategic partnerships as evidence of long-term value, while bears focus on regulatory risks and the sustainability of revenue models tied to Treasury yields.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as investors debate its high-risk nature, with some betting on explosive growth while others warn of a potential pump-and-dump scheme. Discussion centers on navigating low liquidity, managing volatility, and finding entry points on decentralized platforms.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is gaining traction as community members actively debate its relative performance against other niche tokens and meme-focused assets within the crypto ecosystem.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant market volatility as investors weigh the potential competitive pressure from a new energy drink launched by Costco against the company's established brand loyalty and strong growth metrics. While some in the community express frustration over recent price weakness and speculative concerns regarding distributor influence, others view the current dip as a buying opportunity, emphasizing the company's solid fundamentals and ongoing international expansion efforts.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as the community anticipates major upcoming NASA contract awards, specifically for the Lunar Terrain Vehicle (LTV) program, following a recent and substantial CLPS contract win. Investors are actively discussing the company's strong revenue guidance and its pivotal role in NASA's long-term lunar infrastructure plans, leading to high volatility and intense debate between optimistic longs and skeptical shorts regarding the stock's valuation.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is generating significant market interest as community members actively discuss its role in enterprise platforms and the ongoing debate surrounding its regulatory classification as a digital commodity. While some traders are focused on technical setups and accumulation patterns, others are actively debating the broader implications of institutional inflows and the potential for long-term growth within the ecosystem.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is surging as the investment community reacts to highly positive Phase 1 clinical data for its lead oncology candidate, TERN-701, for chronic myeloid leukemia. Investors are actively discussing the potential for a lucrative buyout or partnership as analysts aggressively raise price targets, though some community members remain cautious, debating the long-term valuation risks associated with early-stage assets and the potential for upcoming share dilution.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is seeing heightened volatility as the community remains deeply divided over the companys pivot to a cash-heavy holding model and the upcoming shareholder vote on the CEO's compensation package. While some bulls are optimistic about long-term profitability and potential acquisitions, many retail investors are expressing frustration over stagnant price action, the absence of an earnings call, and the lack of a clear operational roadmap.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Adma Biologics is trending as shareholders react to a recent activist short report alleging revenue manipulation and channel stuffing, leading to intense community debate over whether the company needs to issue an immediate rebuttal. While some investors fear the report's potential to drive institutional selling, many are calling for management to address the claims directly to restore confidence and force a potential short squeeze.

Robinhood Ventures Fund I invest in companies located in the United States. The fund focuses on a broad range of sectors and industries. It provides financing for early stage transactions.

Robinhood Ventures Fund I - Common shares of beneficial interest

Investors are actively weighing the potential of Robinhood Ventures Fund I against the newly listed innovation funds, fueling intense debate over portfolio quality and the fund's discount to net asset value. Sentiment remains split between those holding for long-term exposure to private tech companies and those frustrated by the fund's lackluster debut and performance relative to peers.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bio-Path Holdings Inc.’s stock (BPTH) soared over 150% Thursday afternoon, hitting levels last seen in August, making it the second-biggest gainer across U.S. exchanges.&nbsp;The surge followed the company’s announcement of promising preclinical data for its drug candidate BP1001-A, targeting obesity and related metabolic disorders in Type 2 diabetes patients.The preclinical studies revealed that BP1001-A enhances insulin sensitivity by downregulating growth factor receptor-bound protein 2 (Grb2), which plays a crucial role in insulin signaling.&nbsp;By targeting Grb2, the treatment demonstrated potential in lowering blood glucose levels. This approach is seen as a promising alternative to current weight loss drugs that struggle to show efficacy in obese patients with Type 2 diabetes.Bio-Path CEO Peter Nielsen said, “The failure of leading weight loss medications to induce weight loss in obese patients who have Type 2 diabetes creates a compelling need for an alternative method of lowering blood glucose in obese patients who have Type 2 diabetes.”"We are excited by the rapid progress we have made advancing BP1001-A as a potential treatment for obesity and related metabolic diseases in Type 2 diabetes patients based on previous BP1001-A preclinical studies as they support our continued and rapid development of this promising program,” he added.The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BPTH_sentiment_and_messahe_volume_Dec_20_4b61c6386d.png" alt="BPTH sentiment and messahe volume Dec 20.png" width="1318" height="324"><figcaption>BPTH sentiment and message volume Dec 20 as of 2:00 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, Bio-Path became a trending symbol, with sentiment turning ‘extremely bullish’ as message volume reached its highest point this year.&nbsp;Many retail investors expressed enthusiasm for accumulating the stock during after-hours trading to counter potential short-seller activity.<stembedurl>https://stocktwits.com/Henry666666/message/597231530</stembedurl><stembedurl>https://stocktwits.com/dpell17/message/597231919</stembedurl><stembedurl>https://stocktwits.com/Trader1141/message/597221863</stembedurl>In October, Bio-Path shares surged after the company announced its development program for BP1001-A. While the drug is being explored for obesity and metabolic diseases, it is also undergoing a Phase 1/1b trial for solid tumors.Despite the dramatic single-day rally, the stock remains down over 80% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market data with uptrend vector | Illustration Source: Getty Images

Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode

The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.

Equity

Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Current Price	$0.21
Prev Close	$0.6332
Open	$0.3645
Dividend Yield	0.00%
50-Day Moving Average	$0.21
Beta	0.20
Avg. Volume	0.00
PE Ratio	-0.14

52-Week High	$0.21
52-Week Low	$0.21
Market Capitalization	$600,740.00
EPS (Annual)	-$4.12
Price to Book	-0.24
Revenue Per Employee	$0.00

BPTH
Bio-Path Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BPTH News

BPTHBio-Path Holdings Inc